邮件订阅 RSS 中文 | English
高级检索
宋东强, 蔡瑜, 张顺财. 血清HBeAg与预防性肝动脉化疗栓塞后肝细胞癌复发的相关性[J]. 中国临床医学, 2018, 25(3): 470-474.
引用本文: 宋东强, 蔡瑜, 张顺财. 血清HBeAg与预防性肝动脉化疗栓塞后肝细胞癌复发的相关性[J]. 中国临床医学, 2018, 25(3): 470-474.
shu
Correlationship between serum HBeAg level and tumor recurrence after adjuvant transcatheter arterial chemoembolization in hepatocellular carcinoma patients[J]. Chin J Clin Med, 2018, 25(3): 470-474.
Citation: Correlationship between serum HBeAg level and tumor recurrence after adjuvant transcatheter arterial chemoembolization in hepatocellular carcinoma patients[J]. Chin J Clin Med, 2018, 25(3): 470-474.
shu

血清HBeAg与预防性肝动脉化疗栓塞后肝细胞癌复发的相关性

Correlationship between serum HBeAg level and tumor recurrence after adjuvant transcatheter arterial chemoembolization in hepatocellular carcinoma patients

    摘要
  • 摘要: 目的：分析乙肝阳性肝细胞癌（hepatocellular carcinoma，HCC）患者根治性切除术后预防性肝动脉化疗栓塞（transcatheter arterial chemoembolization，TACE）治疗后血清乙型肝炎病毒E抗原（HBeAg）与肿瘤复发的相关性。方法：回顾分析2015年6月至2016年6月在复旦大学附属中山医院于HCC根治性切除术后行预防性TACE治疗的197例乙肝阳性HCC患者的临床资料。按照HBeAg表达情况，将患者分为HBeAg阴性组(160例)、HBeAg 阳性组（37例），分析HBeAg与预防性TACE术后HCC复发的相关性。结果：HBeAg阳性患者的中位无复发生存期（recurrence-free survival time, RFS）为（4.57±0.35）个月，HBeAg阴性患者为（5.80±0.85）个月，差异有统计学意义（P=0.046）。Cox多因素回归分析显示，微血管侵犯（microvascular invasion,MVI）高危（P=0.008）及HBeAg（P=0.009）是乙肝阳性HCC预防性TACE治疗后HCC复发的独立危险因素。结论：对于HCC根治性切除术后的慢性乙肝患者，HBeAg是影响其预防性TACE治疗后肿瘤复发的独立危险因素。

     

    Abstract: Objective：To investigate the correlation between HBeAg and tumor recurrence after adjuvant transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC) patients after liver resection. Methods：Clinical data of 197 HCC patients with hepatitis B after liver resection from June 2015 to June 2016 in Zhongshan Hospital, Fudan University were analyzed retrospectively. According to the levels of HBeAg, patients were divided into HBeAg negative group (160 patients) and HBeAg positive group (37 patients). The correlation between HBeAg and tumor recurrence after adjuvant TACE was analyzed. Results：The median recurrence-free survival time (RFS) in the HBeAg positive group was (4.57±0.35) months, and the median RFS in HBeAg negative group was (5.80 ± 0.85) months. The difference in RFS between the two groups was statistically significant (P=0.046). Cox proportional hazard regression analysis showed that microvascular invasion (MVI,P=0.008) and HBeAg level (P=0.009) were the independent risk factors for tumor recurrence after adjuvant TACE in HCC patients after liver resection. Conclusions：HBeAg level might be an independent risk factor for tumor recurrence after adjuvant TACE in HCC patients with hepatitis B after liver resection.

     

    • HTML全文
    • 参考文献(0)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回